{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:06:19Z","timestamp":1784635579075,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.hrthm.2026.06.020","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:19:22Z","timestamp":1782231562000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-4074","authenticated-orcid":false,"given":"Yeela","family":"Talmor-Barkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kornowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Witberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Skalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagai","family":"Rossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Yacovzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.06.020_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.hrthm.2026.06.020_bib2","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.06.020_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.06.020_bib4","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs stroke prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib5","first-page":"287","article-title":"Oral anticoagulation in chronic kidney disease and atrial fibrillation","volume":"115","author":"Heine","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.hrthm.2026.06.020_bib6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.06.020_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.kint.2016.10.017","article-title":"The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation","volume":"91","author":"Keskar","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.hrthm.2026.06.020_bib9","article-title":"Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care","volume":"360","author":"Kumar","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.hrthm.2026.06.020_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ndt\/gfu334","article-title":"Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation","volume":"30","author":"Genovesi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hrthm.2026.06.020_bib11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.06.020_bib12","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.113.004777","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.06.020_bib13","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.06.020_bib14","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1161\/STROKEAHA.117.017114","article-title":"Warfarin use in patients with atrial fibrillation undergoing hemodialysis: A nationwide population-based study","volume":"48","author":"Yoon","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.hrthm.2026.06.020_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib18","first-page":"58","article-title":"[Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation]","volume":"34","author":"Di Lullo","year":"2017","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.hrthm.2026.06.020_bib19","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/S0140-6736(17)30876-0","article-title":"Digital health nation: Israel\u2019s global big data innovation hub","volume":"389","author":"Balicer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.06.020_bib21","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1093\/eurheartj\/ehaa650","article-title":"Nomenclature for kidney function and disease-executive summary and glossary from a Kidney Disease: improving Global Outcomes (KDIGO) consensus conference","volume":"41","author":"Levey","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.06.020_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.hrthm.2026.06.020_bib23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.hrthm.2026.06.020_bib24","article-title":"An evaluation toolkit to guide model selection and cohort definition in causal inference","author":"Shimoni","year":"2019","journal-title":"arXiv [Preprint]"},{"key":"10.1016\/j.hrthm.2026.06.020_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","author":"Singer","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2016.03.019","article-title":"Effect of apixaban on brain infarction and microbleeds: Averroes-MRI assessment study","volume":"178","author":"O\u2019Donnell","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrthm.2026.06.020_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.06.020_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ehjcvp\/pvac063","article-title":"Head-to-head efficacy and safety of Rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial","volume":"9","author":"Talmor-Barkan","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hrthm.2026.06.020_bib29","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib30","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.06.020_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847286","article-title":"Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"9","author":"Elfar","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hrthm.2026.06.020_bib32","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.hrthm.2025.02.009","article-title":"Efficacy and safety of DOACs vs vitamin K antagonists in patients with atrial fibrillation and chronic kidney disease undergoing hemodialysis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","volume":"22","author":"Bulhoes","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.06.020_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ckj\/sfad004","article-title":"Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D","volume":"16","author":"Welander","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.hrthm.2026.06.020_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.hrthm.2025.01.045","article-title":"Effectiveness and safety of apixaban and warfarin in patients with new-onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease","volume":"22","author":"Wu","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.06.020_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100813","article-title":"Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease","volume":"3","author":"Kreutz","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.hrthm.2026.06.020_bib36","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/cells12121581","article-title":"The role of inflammation in CKD","volume":"12","author":"Kadatane","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.hrthm.2026.06.020_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2013.09.006","article-title":"Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue","volume":"718","author":"Bukowska","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2026.06.020_bib38","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jphs.2018.07.002","article-title":"Factor Xa inhibition by Rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia","volume":"137","author":"Imano","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.hrthm.2026.06.020_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240669","article-title":"Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models","volume":"15","author":"Daci","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2026.06.020_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fcvm.2020.00114","article-title":"Comparison of inflammatory mediators in patients with atrial fibrillation using warfarin or Rivaroxaban","volume":"7","author":"Martins","year":"2020","journal-title":"Front Cardiovasc Med"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126024884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126024884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:36:24Z","timestamp":1784633784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126024884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S1547527126024884"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.06.020","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}